Prostate cancer has become one of the most common malignant diseases in Western countries. In Danish men. prostate cancer is the second most commonly diagnosed non-skin cancer disease (Engeland et al. 1993 ) and the second leadincg cause of male cancer death (Engeland et al. 1995) . Nevertheless. the frequency of latent carcinoma of the prostate at autopsv has been found to be manx times greater than w-ould be expected from the incidence and mortalitv of clinical prostate cancer (Breslow-et al. 1977 ). The present capability to identifx prostate cancer patients at an earlv and theoreticaflx curable stage. without beinc able to discriminate between latent and potentially aggressixe tumours. has resulted in the present dilemma of this cancer disease (Borre et al. 1998). Therefore. to make an aggressive therapeutic approach to1k-ards localized prostate cancer beneficial. development of sensitive prognostic new markers is of great importance.
Experimental evidence has demonstrated that tumour growth and dissemination are dependent on anriogenesis. the formation of new blood vessels from an extant microvascular bed (Folkman. 1990) . MicroVessel densitv (MVD) has been shown to correlate w-ith the clinical outcome of several human neoplasms. e.g. cutaneous melanoma (Srivastava et al. 1988 ) and breast carcinoma (Weidner et al. 1991 : Fox et al. 1994 : Heimann et al. 1996 . In prostate carcinoma. MVD has been show n to correlate with stage (Weidner et al. 1993 : Brawer et al. 1994 . as well as progression after radical prostatectomy (Silberman et al. 1997 ).
The purpose of this study %vas to investigate the association betnveen MVD and the clinical stage. histopathological grade and survival in patients w ith prostate cancer follow ed expectantly.
MATERIALS AND METHODS Patients
A complete population of patients w ith prostate cancer consisting of 719 inhabitants of Aarhus County xxere diagnosed in a 5-xear period (1 Januarx 1979 to 31 December 1983). The patients haxe been retrospectively followed from the time of diagnosis until death. From this previously described prostate cancer patient population (Borre et al. 1997) . 221 patients (31%7c). irrespective of tumour stage. were included in the present studx. Thex represent a cohort xxith axvailable histological tumour tissue obtained at diagnosis as w-ell as complete clinical information. The tumours have been retrospectively classified (Borre et al. 1997) according to the tLICC 1992 classification system (Hermanek and Sobin. 1992 ).
x hereas the orininal histopathological malignancy grade according to WHO (Mostofi et al. 1980) was used. The patients have been followed expectantly and their symptoms treated palliativelv only. A total of 108 (49%c) patients received endocrine treatment durinc disease.
Specimens
Transurethral resected prostate (TURP) specimens for the immunostaininc procedures w ere retrieved from the formalinfixed. paraffin-embedded tissue used for the original histopathological grading. Without know-ledge of the clinical outcome. one representatixe section (4 gm thick) per patient w-as chosen. The study w as carried out w-ith ethics comnmittee approval. in a buffer of 10 nrm sodium citrate. pH 6.0. for 3 x 5 min at 650 W. After 20 min cooling at room temperature. the slides were rinsed with Tris-hydroxymethyl)aminomethane. Sigma 7-9 (Tris). and phosphate-buffered saline (PBS) 1:9. The tissue was then incubated in 2% hydrogen peroxide in ethanol (99%) for 20 min at room temperature. followed by incubation with the peroxidase-conjugated primary antibody (vWF. Dako polyclonal P226. Dako) diluted 1:30 in antibody diluent code S0809. Dako. for 18 h at 40C in a humidity box. The slides were rinsed twice for 5 min in Tris/PBS and incubated for 10 min in 5 ml of 0.8% 3-amino-9-ethylcarbazole (Sigma a-5754) solution, diluted 1:20 in acetatebuffered saline and 3 gil hydrogen peroxide was added. As the end products were soluble in organic solvents, an aqueous counterstain with Mayer's haematoxylin and a Dako Glycergel (code no. C0563) was finally used.
Quanttaton of MVD
The most vascularized areas ( hotspots') were identified using a low high-power field magnification (x 40-x 100). The MVD was quantified at both x 200 and x 400 magnification high-power field (x 10 ocular and x 20/x 40 objective) using a 10 x 10 grid in the eyepiece. The grid covered an area of 0.25 and 0.0625 mm2 respectively. Any red-stained vessels that were clearly separated from adjacent microvessels. occurring within the grid. were then counted. The presence of a vessel lumen was not necessary although usually present (Figure 1 ). The blinded procedure was done by a single observer (MB). The method was validated in a methodical study (Offersen et al. 1998 Figure 1 ) and at x 400 magnification (0.0625 mm2) the median MVD was 17 (range 6-60). There was a good correlation between the two counting areas (0.25 mm' or 0.0625 mm2) (Spearman correlation coefficient = 0.88; P < 0.001). Irrespective of the counting area. the MVD was highly significantly associated with clinical stage (P < 0.0001), histopathological malignancy grade (P < 0.0001) and cause of death (P < 0.0001). Taking this mutually significant accordance of the MVD based on both counting areas into consideration, the following text and analyses refer to MVD as detennined at x 200 magnification (0.25 mm2). MVD was dichotomized using the median count as the cut-off to define MVD 'low' and 'high'. Table 1 demonstrates the distribution of MVD 'low' and 'high' and the clinical characteristics in the entire prostate cancer population. as well as in the subpopulation consisting of patients with theoretically curable clinically localized disease. MVD was significantly (P < 0.0001) associated with all characteristics in all 221 patients. while a similar correlation was less pronounced in the subgroup of patients with clinically localized disease. MVD remained statistically associated with the cause of death (P = 0.0005) and none of the patients categorized as MVD 'high' survived the observation period. No statistically significant difference (P = 0.7) was found between the MVD categories 'low' and 'high' for age at presentation of prostate cancer. MVD was associated with both overall (P < 0.0001) and diseasespecific survival (P < 0.0001) in the entire population (Figure 2A ). Focusing solely on the 125 patients with clinically localized prostate cancer. MVD was found to be significantly (P = 0.0001) correlated with disease-specific survival only ( Figure 2B ). while Britsh Journal of Cancer (1998) 78(7), 940-944 0 Cancer Research Campaign 1998 Table 1 Clinical characteristics at diagnosis and cause of death in the previously described original complete prostate cancer population (Borre et al. 1997 no such correlation (P = 0.07) existedAiIth overall survival. Figure  2C demonstrates the significant (P < 0.0001) correlation between MVD and disease-specific survival in 96 patients suffering from advanced disease. The association betseen MVD and overall survixal w-as also significant (P = 0.0001) within the same subgroup of patients. Based on the knowledge of the great heterogeneity of prostate cancer (Bvar and Mostofi. 1972) and the demonstration of a sianificantlv higher MVD at the centre of the prostate tumour than at the pernphenr (Siegal et al. 1995) . the MVD was quantified as the maximum count in microvessel positive 'hotspot areas of the tumour.
As a cut-off point representing the median *-alue can be used w ithout introducing bias evaluating prognostic factors (Simon and Altman. 1994) MVD 'lo, and 'high' groups were defined by dividing the patients into two equal groups using the median MVD. The survival plots in Figure 2A- (1996) and Fox et al (1994) . Like Weidner et al (1993) (Brawer et al. 1994) . By a similar conversion of the NVD originally measured in both areas in the current studv. the ratios of the mean MVD per mm' between organ-confined and non-organ-confined tumours were nearlv identical (about 0.7) to the result of Brawer et al ( 1994) .
Cancer Research Campaign 1998 Silberman et al ( 1997) have demonstrated that MYD correlates wvith progression after radical prostatectomy in 87 carcinomas.
The anti-CD3 1 -immunostained microVessels were quantified in 'hotspot' areas (3.14 mm'). (Vermeulen et al. 1996) . However. information will be lost if the counting areas do not match the size of the hotspots. As proposed by Vermeulen et al (1996) . a standardization of angiogenesis quantification is necessan to facilitate confirmation of the sugagested prognostic value of MVD in prospective controlled trials. By standardizinu and simplifying the scoring of MVD. it will probably become a useful and important progynostic marker in future. It should be emphasized that the current data are based on material primarily removed by TUtRP. while the future clinical utility of MVD. together with several other prognostic mark-ers. will be dependent on biopsy techniques. which migrht tum out to be a critical issue caused by the relative lack of material from this distinctly heterogeneous cancer.
Despite the risk of inaccuracy in data due to retrospectively obtained patient characteristics. as well as immunohistochemical quantification of angiogenesis. the current results of the association between angriogenesis as measured by MVD and survival in patients subjected to watchful waiting suggest that the pattem of neovascularization is important in the natural historv of prostate cancer. Angiogenesis. as a predictor of the spontaneous clinical outcome of clinically localized prostate cancer patients. should be included in the decision of future therapeutical strategies of the individual prostate cancer patient.
